Rapport Therapeutics Scores Bipolar Mania Breakthrough as RAP-219 Advances Toward Phase 3
Rapport Therapeutics (NASDAQ:RAPP) delivered a major clinical milestone, announcing positive Phase 2 results for RAP-219 in adults experiencing acute bipolar mania. The randomized, double-blind, placebo-controlled trial enrolled 253 adults with bipolar I disorder and met both its primary and secondary endpoints, strengthening the case for a potential new treatment in a field where tolerability remains a significant challenge. With additional Phase 3 programs already underway in epilepsy, Rapport is building a broader development story around a single investigational drug with multiple potential applications.